Reality of the ASPIRE Study
Video Categories: ASH 2014
Ajai Chari, MD, at the Mount Sinai School of Medicine in New York, deliberates on the results of the ASPIRE study as the most important thing to come out of ASH for the myeloma community. He mentions that although the study has very positive indications, the therapy isn’t really appropriate for a large portion of the myeloma population. The most practice changing piece of the study may be regarding the proven safety of carfilzomib.
January 4, 2017
Wouter de Herder, MD, discusses transient and long-term side effects for patients undergoing this type of treatment.
March 31, 2015
Alexander Bastian discusses the critical nature of value and cost-effectiveness in cancer care, which he says is a difficult challenge and must include patients and providers.